Is Entero Healthcar overvalued or undervalued?

As of 20 June 2025, Entero Healthcare has moved from an attractive to a very attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE ratio of 51.31, an EV to EBITDA of 28.76, and a PEG ratio of 0.36, indicating strong growth potential relative to its price.
In comparison to its peers, Entero Healthcare's PE ratio is significantly higher than TCS at 25.59 and Infosys at 25.22, which suggests that while Entero is priced for growth, it may also reflect a premium for its perceived future performance. Additionally, the EV to EBITDA ratio of 28.76 is higher than that of HCL Technologies at 17.63, reinforcing the notion that Entero is positioned for growth but at a higher valuation compared to its peers. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -20.8% compared to the Sensex's 5.46%, the underlying valuation metrics suggest that Entero Healthcare presents a compelling investment opportunity.